Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Novartis to Acquire IFM Tre for its Clinical and Preclinical

Shots:  Novartis acquires IFM Tre, in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19 The focus of the acquisition is to expand Novartis’ immunomodulatory portfolio with the addition of IFM Tre’s one clinical (IFM-2427) and two preclinical programs of […]Read More

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene

 Shots: StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three […]Read More

Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH)

Shots: Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS) The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and […]Read More

AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi

Shots: Daiichi Sankyo to receive $1.35B upfront, $5.55B as regulatory & commercial milestones making the total deal value $6.9B. AstraZeneca to get WW co-development and co-commercialization rights for Daiichi’s trastuzumab deruxtecan (Ex- Japan) with equal cost & profit sharing The focus of the collaboration is to develop trastuzumab deruxtecan for HER2+ breast and gastric cancer […]Read More

Johnson & Johnson (J&J) Vision Launches Acuvue Oasys with Transitions

Shots: J&J Vision’s Acuvue Oasys with transitions light intelligent technology is evaluated in 1000 patients results demonstrated 67% performs better in doing physical activities, 55% feel stress exposing bright & harsh light, 56% adjust light condition quickly On Apr 11, 2018 J&J Vision collaborated with Transitions Optical Limited to develop Acuvue Oasys, a lens providing […]Read More

Apple Launches its Watch Series 4 Enabled with ECG App

Shots: The ECG app on Apple Watch Series 4 is evaluated in 600 patients resulted in 98.3% sensitivity in classifying AFib, 99.6% specificity in classifying sinus rhythm, 87.8% of recordings classified by the ECG app The irregular rhythm notification function was assessed in the Apple Heart study enrolled with 400,000 candidates and demonstrated 0.5% irregular […]Read More

Chugai’s Risdiplam Receives MHLW’s Orphan Drug Designation for Spinal Muscular

Shots: The MHLW’s ODD follows P-II/III (FIREFISH, SUNFISH) study assessing Risdiplam in patients with  spinal muscular atrophy (SMA) in Japan  Chugai & Roche collaborated for the clinical development Risdiplam, first oral systemic therapy for SMA Risdiplam (RG7916) is survival motor neuron-2 (SMN2) splicing modifier targeted to increase SMN protein levels in CNS and has received […]Read More

PharmaShots Weekly Snapshot (March 25-29, 2019)

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders Published: March 29, 2019 | Tags: Takeda, Signs, Multi- Target Agreement, StrideBio, Develop, Gene Therapies, Neurological Diseases Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study Published: March 29, 2019 | Tags: Mitsubishi Tanabe Pharma, MTPA, Collaborates, Massachusetts […]Read More

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for

Shots: The P-III study involves assessing JZP-258 vs PBO in 201 patients with narcolepsy + cataplexy prior treated with Xyrem, naive to Xyrem, or with/without anti-cataplectic treatments The P-III study results: met its 1EPs & 2EPs; reduction in no. of cataplexy attacks in a week and Epworth Sleepiness Scale score JZP-258 is an oxybate therapy […]Read More